Experimental kidney drug DF-003 enters first human safety trial
NCT ID NCT05997641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety and metabolism of an experimental oral drug called DF-003 in 96 healthy volunteers. The drug aims to reduce inflammation and kidney scarring, potentially offering a new treatment for chronic kidney disease. Participants receive either a single or multiple doses of DF-003 or a placebo, and are closely monitored for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DF-003 (an experimental oral drug that targets inflammation and fibrosis)
What this could lead to
If successful, this could pave the way for a new treatment for chronic kidney disease by reducing inflammation and kidney scarring.
What could go wrong
This is a very early Phase 1 trial in healthy people, so it only tests safety and how the drug is processed. It does not yet test if it works for kidney disease, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences Clinical Los Angeles, Inc
Cypress, California, 90630, United States